Capricor Therapeutics, Inc. (CAPR) – Buy Target – $2.25 or better

Buy Target – $2.25 or better
Sell Target – TradersPro Sell Signal

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. The company’s development stage drug candidates for cardiosphere-derived cells include CAP-1002 that completed phase I/II clinical trial in subjects with DMD; phase I clinical trial for treating heart failure; and phase I/II clinical trial in subjects with myocardial infarction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.


© Copyright 2020 Investing is Inherently Risky - There are risks inherent in all investments, which may make such investments unsuitable for certain persons. These include, for example, economic, political, currency exchange, rate fluctuations, and limited availability of information on international securities. You may lose all of your money trading and investing. Do NOT enter any trade without fully understanding the worst-case scenarios of that trade. And do NOT trade with money you cannot afford to lose. Past performance of an investment is not necessarily indicative of its future results. No assurance can be given that any implied recommendation will be profitable or will not be subject to losses.